Strongbridge Biopharma releases phase 3 trial data for their Endogenous Cushing’s syndrome treatment, COR-003. The risk is extremely high, as the data released will most likely make the stock price go up/down by at least 50%. However, if we simply play the anticipation, it is pretty much a 20% guarantee. I am planning on selling most of my position on the 19th, then selling the rest on the 22nd at the market open. Remember this is a biotech penny stock, so really anything can happen. Good Luck!
